Table 1 Characteristics of patients between drusen area categories, as based on the drusen coverage in the ETDRS grid at baseline.

From: Genetic risk score has added value over initial clinical grading stage in predicting disease progression in age-related macular degeneration

 

<1% drusen coverage (n = 73)

1–10% drusen coverage (n = 79)

>10% drusen coverage (n = 25)

P value

Age, mean (SD), years

70.1 (5.3)

71.0 (5.0)

70.5 (4.7)

0.54

Sex

0.022

  Female (n (%))

34 (46.6%)

53 (67.1%)

17 (68.0%)

  Male (n (%))

39 (53.4%)

26 (32.9%)

8 (32.0%)

  BMI, mean (SD), kg/m2

27.2 (4.3)

26.5 (3.9)

26.3 (3.6)

0.49

Smoking history

0.16

  Current smoking (n (%))

4 (6.3%)

7 (9.7%)

1 (4.5%)

  Smoked in the past (n (%))

22 (34.4%)

21 (29.2%)

2 (9.1%)

  Never smoked (n (%))

37 (58.7%)

44 (61.1%)

19 (86.4%)

Non-advanced AMD stage

<0.001

  Early AMD (n (%))

55 (75.3%)

43 (54.4%)

5 (20.0%)

  Intermediate AMD (n (%))

18 (24.7%)

36 (45.6%)

20 (80.0%)

GRS, mean (SD)

0.98 (1.00)

1.10 (1.32)

1.72 (1.37)

<0.001

  1. The non-advanced AMD stage was graded with the AREDS basic clinical classification scale. The GRS includes 52 AMD-associated variants.
  2. AMD Age related Macular Degeneration; AREDS Age-Related Eye Disease Study; AMD Age related Macular Degeneration; BMI Body Mass Index; ETDRS Early Treatment Diabetic Retinopathy Study; GRS genetic risk score; SD Standard Deviation.
Back to article page